CNS Market Access in India: Government investment into CNS services set to stimulate market growth

CNS Market Access in India: Government investment into CNS services set to stimulate market growth


June 28, 2011
99 Pages - SKU: DFMN6462600
License type:
Online Download      US $5,700.00
Global Site License      US $14,250.00
Countries covered: India

Introduction

India's growing elderly population and expanding middle class population makes the country an attractive market for manufacturers of CNS products. Indeed, the number of CNS drugs approved grew steadily over 1999-2009. Key CNS drug launches to have taken place in India in recent years include ramelteon, rasagiline, desvenlafaxine extended release and paliperidone extended release.

Features and benefits
  • Quantify the prevalent cases of key CNS conditions in India in 2010.
  • Review the current treatment of key CNS conditions in India and published treatment guidelines.
  • Identify the major multinational and domestic players in the Indian CNS market. Understand the composititon of their CNS portfolios.
  • Examine the major strengths and weaknesses of the current Indian CNS market. Understand the key opportunites and threats facing developers.
  • This report is authored by an analyst and epidemiologist based in Hyderabad, India.
Highlights

Stigma attached to psychiatric conditions in India deters patient presentation, resulting in underdiagnosis and undertreatment of mental health conditions. In addition, delivery of neurological, psychiatric and pain services in India are hampered by a severe shortage of professionals qualified to treat central nervous system (CNS) disorders.

The Indian government's increasing focus on mental illness and the implementation of the National Mental Health Programme represent key opportunities for multinational pharmaceutical companies seeking to penetrate the Indian market with a strong portfolio of CNS drugs.

The Indian CNS market is attractive to drug developers on account of the country’s growing elderly population. Since several CNS conditions (such as Alzheimer’s disease, depression, epilepsy, and pain) are prevalent in the elderly population, growth of this population segment will present a sizable patient population for drug developers to target.

Your key questions answered
  • How many prevalent cases of key CNS condititons are there in India? Which indication offers the greatest patient potential to developers?
  • Which are the most active multinational and domestic pharmaceutical companies in the Indian CNS market?
  • How are neurology, psychiatry and pain services organized and delivered in India? What are the typical patient care pathways for key CNS conditions?
  • What are the key opportunities for existing and prospective players? What are the major threats to the uptake of CNS drugs in India?
  • What strategies can companies implement in order to achieve maximum penetration in the Indian CNS market?
Please note: this is delivered as a Zip file.



More CNS/Neurology reports by Datamonitor

The Depression Market Forecast to 2021 by Datamonitor
The Depression Market Forecast to 2021 Introduction Datamonitor Healthcare values the depression market, comprising of traditional major depressive disorder, as well as treatment-resistant major ...
Treatment Algorithms: Postherpetic Neuralgia by Datamonitor
Prescribing trends reveal that patients with PHN are typically initiated on monotherapy. Since no single therapy provides sufficient efficacy, physicians increasingly turn to combination therapy ...
Market and Product Forecasts: Top 10 Neurology Brands: 2011–21 by Datamonitor
IntroductionThe diverse field of neurology hosts numerous disorders with substantial unmet clinical need, creating a complex but lucrative market. Considerable rewards are available for the ...
Central Nervous System Drug Delivery Specialists by Datamonitor
IntroductionThe blood-brain barrier (BBB) is so effective at limiting the passage of exogenous substances that many drugs with the potential to treat CNS diseases are ...
See all reports like this >>

More India CNS/Neurology reports

The 2009-2014 Outlook for Drugs for Alzheimer’s and Parkinson’s Diseases in India by Icon Group International, Inc.
This econometric study covers the latent demand outlook for drugs for Alzheimer’s and Parkinson’s diseases across the states, union territories and cities of India. Latent ...
See all reports like this >>

More India reports

The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: India by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Spirits - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Spirits - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) ...
Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...
See all reports like this >>